According to a recent LinkedIn post from vopemed, CEO and Co‑Founder Amy Lorincz is scheduled to present at LSI USA ’26, described as a premier medtech partnering event. The session, set for Tuesday, March 17 from 3:55 to 4:04 PM in Monarch 3, is positioned as an opportunity to engage key strategic partners and investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The company’s LinkedIn post highlights vopemed’s focus on building a “foundational vision layer” for surgical AI, including real‑time digital smoke removal and pre‑processing of surgical video inputs. The post suggests these capabilities aim to support safer procedures and more robust deployment of AI models in the operating room.
As shared in the post, vopemed’s participation at a curated investor and partner forum such as LSI USA ’26 may enhance its visibility among leading health systems and medtech corporates, including sponsors like Cedars‑Sinai, Mayo Clinic, Medtronic and Edwards Lifesciences. For investors, this type of exposure can be relevant to assessing future partnership potential, clinical validation pathways and capital‑raising prospects.
The networking call‑to‑action in the post, inviting attendees to connect directly with the CEO, underscores an emphasis on relationship building at an early stage of the company’s trajectory. If successful, such interactions could translate into pilot collaborations, strategic alliances or follow‑on investment interest, all of which may influence vopemed’s growth outlook within the surgical AI and broader medtech ecosystem.